16.05.2012 - Britain's largest drugmaker GlaxoSmithKline will pay about €75m in cash to acquire Cellzome AG completely.
London/Heidelberg/Cambridge – The pharma already owns about 20% of all outstanding shares. The privately owned biotech with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK's R&D organisation. GSK knows its acquisition target quite well, as both partners have maintained a research cooperation for four years.
"The acquisition of Cellzome adds significantly to our scientific capabilities and capacity to characterise drug targets and provides the opportunity to further enhance GSK's ability to bring medicines to patients in a more effective manner," said John Baldoni, senior vice president, Platform & Technology Science, at GSK.
Cellzome's proteomics technologies can be used throughout drug discovery from screening to selectivity profiling of compounds in different cells and also in patient samples. The technologies that Cellzome has developed differ from other traditional methods used in early drug discovery by assessing drug interactions with target proteins in a setting which more closely represents that found in a whole biological system. This allows scientists to observe how candidate drugs affect both intended and non-desired targets in a close-to-physiological environment and may pinpoint potential safety issues earlier in the process.
However, Cellzome shareholders, including Glaxo, intend to create a spin-off company, which "would hold the rights to certain of Cellzome's assets and activities that GSK does not wish to progress".